Evidence map›Paper›PMID 40388674›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Small Nuclear Ribonucleoprotein Autoantibody Associated With Blood-Nerve Barrier Breakdown in Guillain-Barré Syndrome.

Fumitaka Shimizu, Michiaki Koga, Yoichi Mizukami, Kenji Watanabe, Ryota Sato, Yukio Takeshita, Toshihiko Maeda, Takashi Kanda, Masayuki Nakamori

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fumitaka ShimizuDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID 0000-0003-4163-2939
Michiaki KogaDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID 0000-0002-1356-955X
Yoichi MizukamiCenter for Gene Research, Yamaguchi University, Ube, Japan.ORCID 0000-0002-3290-0754
Kenji WatanabeCenter for Gene Research, Yamaguchi University, Ube, Japan.ORCID 0000-0002-5069-1706
Ryota SatoDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Yukio TakeshitaDepartment of Neurotherapeutics, Yamaguchi University School of Medicine, Ube, Japan.ORCID 0000-0002-0314-550X
Toshihiko MaedaDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Takashi KandaDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID 0000-0001-8919-6377
Masayuki NakamoriDepartment of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID 0000-0003-4714-3044

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesBreakdown of the blood-nerve barrier (BNB) is observed in patients with Guillain-Barré syndrome (GBS); however, the molecular mechanism underlying this phenomenon remains unclear.The aim of this study was to identify antibodies against the BNB-endothelial cells that initiate BNB breakdown in patients with GBS.

methodsWe purified IgGs from the serum samples of patients with GBS (n = 77) during the acute phase, disease controls ([DCs], n = 51), and healthy controls ([HCs], n = 24). Human peripheral nerve microvascular endothelial cells (PnMECs) were incubated with IgG. Molecular changes in PnMECs after GBS-IgG exposure were evaluated using RNA-seq and a high-content imaging system. U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibodies were detected using an ELISA. The clinical information of U1-snRNP antibody-positive GBS patients was verified.

resultsGBS-IgGs significantly increased NF-κB nuclear translocation and permeability of the 10-kDa dextran in PnMECs compared with DC-IgGs or HC-IgGs. RNA-seq analyses of PnMECs demonstrated that NF-κB p65 in the center of the network analysis, snRNPs as upstream genes of NF-κB p65, and CXCR5 as downstream genes of NF-κB p65 were important molecules after GBS-IgG exposure. The protein level of claudin-5 and U1-snRNP was significantly reduced while that of CXCR5 was significantly increased after incubation with IgG from patients with GBS, compared with that from HCs. The rate of U1-snRNP antibody positivity was 36% (28 of 77) in patients with GBS, 7% (2 of 28) in DCs, and 0% (0 of 16) in HCs. The serum titer of snRNP antibody decreased after treatment. Both cerebral spinal fluid protein and albumin quotient (QALB)/QALBLIM were higher in snRNP antibody-positive GBS patients than in snRNP antibody-negative GBS patients. IgG from U1-snRNP antibody-positive GBS patients decreased the barrier function and claudin-5 expression more than that from HCs in an in vitro BNB coculture model. The reduction in U1-snRNP antibody decreased the biological effect of IgG from GBS patients with U1-snRNP antibody on the increased permeability of PnMECs. DISCUSSION: U1-snRNP autoantibodies are associated with the breakdown of BNB in GBS, through the reduction of U1-snRNP and claudin-5 and the induction of NF-κB activation in BNB-endothelial cells. A temporary autoantibody response against snRNP may be boosted by the periodic response to infection in GBS.

Indexed as

AutoantibodiesBlood-Nerve BarrierGuillain-Barre SyndromeRibonucleoprotein, U1 Small NuclearAdultAgedCells, CulturedEndothelial CellsFemaleHumansImmunoglobulin GMaleMiddle AgedAutoantibodiesImmunoglobulin GRibonucleoprotein, U1 Small Nuclear

Identifiers

PMID40388674
PMCPMC12092546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.